Ovid Therapeutics Inc. OVID
Ovid Therapeutics Inc. (Nasdaq: OVID) is a CNS/neurology/psychiatry drug developer. Its lead program, OV329, is in Phase 2 for treatment-resistant focal onset seizures (also TSC-associated seizures, infantile spasms). Its next catalyst on record is OV329: Initiate proof-of-concept study in TSC-associated seizures (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: OV329 — Initiate proof-of-concept study in TSC-associated seizures (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| OV329 (GABA-AT inhibitor) Phase 2 dose-confirmatory study | treatment-resistant focal onset seizures | small molecule | Phase 2 |
| OV329 photosensitivity proof-of-mechanism study | photosensitive epilepsy | small molecule | Phase 2 |
| OV4071 (oral KCC2 direct activator) | schizophrenia / psychosis (initially PDP, LBD psychosis) | small molecule | Phase 1 |
| OV329 TSC-associated seizures study | tuberous sclerosis complex seizures | small molecule | Pre-clinical |
| Other KCC2 activator candidates | CNS disorders | small molecule | Pre-clinical |
Recent results and decisions
- Mar 18, 2026positive 7 mg OV329 cohort (SAD and MAD, 6 active and 2 placebo each) had no treatment-related adverse events; 19 unrelated AEs all mild and transient; no ophthalmic changes.
There were no treatment-related adverse events in the 7 mg cohort, and in a total of 19 unrelated adverse events, all were mild and transient.
Filing - Mar 18, 2026n/a Australian HREC approval and TGA Clinical Trial Notification acknowledged for the OV4071 Phase 1 study (ex-US clearance), with study start in Q2 2026.
OV4071, a first-in-class, oral KCC2 direct activator, received Human Research Ethics Committee approval and acknowledgement of its Clinical Trial Notification from the Australian Therapeutic Goods Administration
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.